Advertisement

Taurine 8 pp 145-154 | Cite as

Evaluation of the Taurine Concentrations in Dog Plasma and Aqueous Humour: A Pilot Study

  • Serge-George RosolenEmail author
  • Nathalie Neveux
  • José-Alain Sahel
  • Serge Picaud
  • Nicolas Froger
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 775)

Abstract

In the 70s, the amino acid taurine was found essential for photoreceptor survival. Recently, we found that taurine depletion can also trigger retinal ganglion cell degeneration both in vitro and in vivo. Therefore, evaluation of taurine levels could be a crucial biomarker for different pathologies of retinal ganglion cells such as glaucoma. Because different breeds of dog can develop glaucoma, we performed taurine measurements on plasma and aqueous humour samples from pet dogs. Here, we exposed results from a pilot study on normal selected breed of pet dogs, without any ocular pathology. Samples were collected by veterinarians who belong to the Réseau Européen d’Ophtalmologie Vétérinaire et de Vision Animale. Following measurements by high-performance liquid chromatography (HPLC), the averaged taurine concentration was 162.3 μM in the plasma and 51.8 μM in the aqueous humour. No correlation was observed between these two taurine concentrations, which exhibited a ratio close to 3. Further studies will determine if these taurine concentrations are changed in glaucomatous dogs.

Keywords

Aqueous Humour Taurine Supplementation Retinal Toxicity Taurine Level Taurine Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

RGC

Retinal ganglion cells

HPLC

High-performance liquid chromatography

12.1 Introduction

Taurine is an enigmatic free sulphur beta amino acid in very high concentration in the retina. In the 70s, this depletion was found to trigger photoreceptor degeneration in cats (Hayes et al. 1975), rats (Pasantes-Morales et al. 1983) and mice (Rascher et al. 2004). This discovery was achieved on cats because this species is unable to synthesize taurine and it can only obtain taurine from its diet. Taurine concentration was therefore examined in dog models of hereditary degenerative diseases (Schmidt and Aguirre 1985) and this supplementation was reported to prevent visual loss in human patients (Pasantes-Morales et al. 2002). Recently, we have correlated the retinal toxicity of the antiepileptic drug, vigabatrin, to a taurine depletion detected in the plasma of vigabatrin-treated rats and patients (Jammoul et al. 2009). However, if some ­hotoreceptor degeneration is part of this retinal toxicity (Ravindran et al. 2001; Duboc et al. 2004), primary affected cells in patients appeared to be retinal ganglion cells (RGCs) (Ravindran et al. 2001; Frisen and Malmgren 2003; Buncic et al. 2004; Wild et al. 2006). Animal models also presented this vigabatrin-induced retinal ganglion cell degeneration, which was suppressed by taurine supplementation (Jammoul et al. 2010). Furthermore, we found that pharmacological blockade of taurine transporter also leads to RGC degeneration (Gaucher et al. 2012). Consistent with these results, some cell loss was reported in the RGC layer in taurine-transporter knockout mice during the massive degenerative process affecting photoreceptors although it was not clear which cells were degenerating in the RGC layer (Heller-Stilb et al. 2002). Finally, we demonstrated that taurine is acting directly on RGCs to induce their survival and that taurine supplementation could rescue RGCs in different animal models of pathologies such as glaucoma or retinitis pigmentosa (Froger et al. 2012). In agreement with these results, a decrease in the retinal taurine concentration was reported in glaucomatous dogs (Madl et al. 2005).

Considering these results on the critical role of taurine in RGC survival, taurine appears as an important biomarker to follow during pathological conditions such as glaucoma. While rodents are commonly used as animal models, large animal models (i.e. dog, cat, pig) have become increasingly attractive to assess efficacy and safety of a variety of treatment modalities that are being considered for clinical trials in human patients. A significant advantage in using the dog is that it enables intraocular drug delivery studies (Le Meur et al. 2007), surgical interventions and in vivo imaging procedures (Rosolen et al. 2001; Rosolen et al. 2012) that cannot always be done in the much smaller rodent eye. Considering dogs, breeds offer a unique possibility to find families with high consanguinity. As a consequence, progressive retinal atrophy (PRA) has been described in more than 100 breeds. These canine forms of retinal diseases share great genetic and phenotypic similarities with their human counterparts. Therefore, dogs provide unique animal models to (i) improve our understanding of the corresponding pathogenic mechanisms and (ii) demonstrate the proof of principle for novel therapeutic strategies. Yet, the dimensions of the canine eye enable intravitreal implantation of devices or injection of compounds in solution that have, respectively, a size or volume targeted to the human eye (Tao et al. 2002).

To prepare the future use of taurine as a biomarker and potential treatment in RGC degenerative diseases, we here report taurine measurements in plasma and aqueous humour samples from different breeds of dogs. This pilot study included 71 healthy pet dogs, without any detected ocular diseases.

12.2 Methods

All procedures were in accordance with the Association for Research in Vision and Ophthalmology statement for the use of animals in ophthalmic and vision research. All animals included in the study were examined by 11 different veterinarians who belong to the REOVVA network (Réseau Européen d’Ophtalmologie Vétérinaire et de Vision Animale) after obtaining informed consent from the owners.

12.2.1 Animals

Results were obtained from a cohort of 69 adult pet dogs (age: min  =  18 months, max 7 years; 33 males and 36 females), among 36 different breeds, without detected ocular pathologies. All animals were in good physical condition and without any visual defect following a complete clinical examination. The complete ophthalmologic examination included slit-lamp and indirect ophthalmoscopy. For aqueous humour collections, animals were sedated with a single intramuscular injection of medetomidine (0.1 mg/kg). The cornea of the right eye was topically anesthetized with two drops of chlorhydrate of oxybuprocaine.

12.2.2 Sample Collections

Blood samples (5 ml) were taken from radial vein in awake dogs and placed in tubes containing EDTA. After centrifugation, plasma was removed and frozen until use for amino acid dosages. Aqueous humour samples were taken on sedated dogs, with a needle (21 G; syringe volume: 0.2 ml) and then directly frozen at −20°C until use for amino acid dosages.

12.2.3 Concentration of Taurine and Its Precursors of Biosynthesis in Plasma and Aqueous Humour

Plasma and aqueous humour were deproteinized with a 30% (w/v) sulfosalicylic acid solution, and the supernatants were stored at −20°C until analysis. Amino acids, including taurine, methionine and cystine, the two latter being precursors in taurine biosynthesis, were measured by ion exchange chromatography.

12.2.4 Statistical Analysis

Data exposed are mean  ±  SEM. One-way ANOVA, followed by a Bonferroni post-hoc, was used to compare mean between groups of dogs. To compare the means of two groups, a Student’s t-test was applied. Differences were considered significant at *p  <  0.05, **p  <  0.01 and ***p  <  0.001.

12.3 Results

12.3.1 Plasmatic Taurine Concentration in Healthy Selected Breed of Dogs

Figure 12.1 illustrates the taurine plasma measurements in the different dogs according to the different veterinarians. In the first stage, plasma samples were collected from 44 dogs (black symbols; Fig. 12.1a) by ten veterinarians, while in the second stage, samples were collected from 25 dogs (blue symbols, Fig. 12.1b) by four veterinarians. When mixing all the different measurements, the averaged taurine plasma concentration was found at 162.3  ±  9.5 μM (mean  ±  SEM, n  =  69). However, the figure shows a surprising group with animals (n  =  5) exhibiting a plasmatic taurine level greater than the average value. For these five animals the difference with the averaged value was statistically significant. Indeed, in this group of dogs, the plasma taurine level was 2.3-fold higher (385.2  ±  16.6 μM, n  =  5; p  <  0.001, red points; Fig. 12.1a) than the remaining dogs 144.9  ±  6.1 μM (mean  ±  SEM, n  =  64). To understand the origin of this major difference, we compared the nature of the dog breeds in this sample with respect to the other cohorts. When all animals were classified according to their sex, males and females were distributed in all groups. In fact, no significant differences were observed in the taurine plasmatic level between sexes (Fig. 12.1b). Similarly, the difference in the group could not be attributed to a bias in the recruitment of particular breed in this group (not shown). We then questioned the food supply in this animal group because taurine can be taken up from our diet. Surprisingly, we found out that it received an unusual seafood-enhanced diet unlike all the other dogs. This result suggests that nutrition can impact the plasmatic taurine level also in dogs.
Fig. 12.1

Taurine plasmatic concentrations in healthy dogs and influence of diet and sex. (a) Graphic representing the plasma taurine concentrations in normal dogs (n  =  69). The black symbols represent values from the first stage while the blue symbols represent values from the second stage of samples. The ellipse represents the values of dogs fed with seafood (n  =  5, p  <  0.01, one-way ANOVA followed by Bonferroni post-hoc test). Data are expressed in micromolar in plasma. (b) Histogram representing plasma taurine concentrations according to sex, showing no difference between males and females. Data expressed as micromolar are mean  ±  SEM from n  =  33 males and n  =  36 females

12.3.2 Plasmatic Concentration of Precursors for Taurine Biosynthesis: Methionine and Cystine in Healthy Selected Breed of Dogs

The concentrations of precursors of taurine biosynthesis were measured on plasma samples collected during the first stage, from the 44 dogs by ten veterinarians. The methionine concentration was found at 61.3  ±  2.3 μM (n  =  44; Fig. 12.2a), while the cystine concentration reached 1.9  ±  0.1 μM (n  =  44; Fig. 12.2b).
Fig. 12.2

Plasmatic concentration of methionine and cystine, the precursor for taurine biosynthesis in healthy dogs. (a) Values of methionine concentration in plasma collected from 44 dogs. The group included into the red ellipse corresponds to dogs fed with seafood (n  =  5). Data are expressed in micromolar in plasma. (b) Values of cystine concentration in plasma collected from 44 dogs. The group included into the red ellipse corresponds to dogs fed with seafood (n  =  5). Data are expressed in micromolar in plasma

Interestingly, in the group of dogs which exhibited a significant increase in plasma taurine (red ellipses, Fig. 12.1a), there are no differences in either methionine concentration (53.3  ±  3.8 μM, mean  ±  SEM, n  =  5, red ellipse; Fig. 12.2a) or cystine concentration (2.0  ±  0.0 μM, mean  ±  SEM, n  =  5 red ellipse; Fig. 12.2b) as compared to the other groups (p  >  0.05, one-way ANOVA).

12.3.3 Taurine Concentration in Aqueous Humour from Healthy Selected Breeds of Dogs

In a subset of 10 dogs from the second stage, samples of aqueous humour were collected and we were able to measure the taurine levels in this liquid. This taurine concentration was measured at 51.8  ±  4.0 μM (mean  ±  SEM; n  =  10, Fig. 12.3).
Fig. 12.3

Plasmatic concentration of taurine in the aqueous humour from healthy dogs. Values of taurine levels in aqueous humour collected from two groups of five dogs. Data are expressed in micromolar in aqueous humour

12.4 Discussion

This pilot study assessed the concentration of taurine and precursors of taurine biosynthesis in the plasma of healthy dogs. We found that the plasmatic taurine concentration is ∼150 μM in normal pet dogs, without any differences between males and females. This value appears in the same range as described in another study on water dogs, in which taurine plasma concentration reached 115 μM (Alroy et al. 2005). In other species, taurine plasma concentration was found lower in cats (52 μM; Earle and Smith 1992), whereas it was higher in rodents like rats (Jammoul et al. 2009) or mice (Gaucher et al. 2012). In humans, the taurine concentration was reported at 39 and 53 μM, while the normal values were considered to range from 40 to 90 μM (Durelli and Mutani 1983; Brons et al. 2004). The normal range appears fairly similar in infants (Jammoul et al. 2009).

The ability of mammals to synthesize taurine from sulphur precursors differs according to species (Huxtable 1989). Dietary sources of taurine are therefore required for species unable to synthesize sufficient taurine such as cats. Previous studies had shown that taurine supplementation can directly increase the taurine plasma level in rodents (Jammoul et al. 2009; Jammoul et al. 2010), as well as in humans (Brons et al. 2004; Shao and Hathcock 2008). Interestingly, our results suggest that the plasma taurine concentration can be manipulated in dogs by introducing a peculiar taurine-rich diet. Indeed, one group of dogs fed with seafood, known to present a high taurine content (Yamori et al. 2009), showed a significant higher taurine plasma concentration. Additional data will be needed to confirm that taurine-enriched diets can increase the plasma taurine concentration in patients.

The discovery of taurine depletion as a cause of retinal degeneration was reported in cats 37 years ago (Hayes et al. 1975). However, in this case, the degenerative process appeared to include only photoreceptors. More recently, the taurine depletion was found to trigger the retinal toxicity of vigabatrin in patients and animals (Jammoul et al. 2009). However, in this retinal toxicity, the primary site of degeneration seems to occur in patients at the level of RGCs even if photoreceptors are also damaged (Ravindran et al. 2001; Wild et al. 2006; Jammoul et al. 2010). We have then demonstrated that taurine directly enhances RGC survival and that a local retinal depletion could thus lead in vivo to RGC degeneration as in glaucoma animal models (Froger et al. 2012). These results are consistent with retinal decrease in taurine concentration in dogs affected with primary glaucoma (Madl et al. 2005). The taurine levels may represent a crucial marker for vulnerability to retinal disease. To start assessing the use of taurine as a marker of glaucoma, we also detected the taurine level in the aqueous humour from healthy dogs with an average value of ∼50 μM. No correlation was found between the taurine levels in plasma and aqueous humour (not shown), which is consistent with the notion that a local retinal deficit can occur despite a normal plasma taurine concentration. This absence of correlation could rely on regulation of the high taurine uptake system located in the retinal pigment epithelium and the endothelial cells (Hillenkamp et al. 2004). Hence the aqueous humour taurine concentration could provide a closer measure to the retinal taurine concentration and thus a more accurate marker for retinal diseases. To answer this question, future studies will evaluate the taurine levels in both the aqueous humour and plasma of glaucomatous dogs.

12.5 Conclusion

Future taurine measurements will be performed in glaucomatous dogs to determine if taurine concentrations could provide a new diagnostic marker for retinal diseases with RGC degeneration leading subsequently to a therapeutic decision for taurine supplementation.

Notes

Acknowledgments

Authors acknowledge Dr. Azoulay, T.; Dr. Boderiou, Y.; Boillot, T.; Cantaloube, B.; Durieux, P.; Goulle, F.; Isard, P-F.; Maller, D.; Michaud, Y.; Philippe, R.; and Rosolen, SG. from the REOVVA group (www.reovva.com) for their contribution to this work. This work was supported by INSERM, Université Pierre et Marie Curie (Paris VI), Fondation Ophtalmologique A. de Rothschild (Paris), Fédération de la Recherche Médicale and Fondation Bailly, the city of Paris and the Regional Council of Ile-de-France.

References

  1. Alroy J, Rush JE, Sarkar S (2005) Infantile dilated cardiomyopathy in Portuguese water dogs: ­correlation of the autosomal recessive trait with low plasma taurine at infancy. Amino Acids 28:51–56PubMedCrossRefGoogle Scholar
  2. Brons C, Spohr C, Storgaard H, Dyerberg J, Vaag A (2004) Effect of taurine treatment on insulin secretion and action, and on serum lipid levels in overweight men with a genetic predisposition for type II diabetes mellitus. Eur J Clin Nutr 58:1239–1247PubMedCrossRefGoogle Scholar
  3. Buncic JR, Westall CA, Panton CM, Munn JR, MacKeen LD, Logan WJ (2004) Characteristic retinal atrophy with secondary “inverse” optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 111:1935–1942PubMedCrossRefGoogle Scholar
  4. Duboc A, Hanoteau N, Simonutti M, Rudolf G, Nehlig A, Sahel JA, Picaud S (2004) Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats. Ann Neurol 55:695–705PubMedCrossRefGoogle Scholar
  5. Durelli L, Mutani R (1983) The current status of taurine in epilepsy. Clin Neuropharmacol 6:37–48PubMedCrossRefGoogle Scholar
  6. Earle KE, Smith PM (1992) The effect of dietary supplementation with cysteic acid on the plasma taurine concentration of cats maintained on a taurine-restricted diet. Adv Exp Med Biol 315:23–32PubMedCrossRefGoogle Scholar
  7. Frisen L, Malmgren K (2003) Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand 81:466–473PubMedCrossRefGoogle Scholar
  8. Froger N, Cadetti L, Lorach H, Martins J, Bemelmans AP, Dubus E et al (2012) Taurine Provides Neuroprotection against Retinal Ganglion Cell Degeneration. PLoS One 7(10):e42017Google Scholar
  9. Gaucher D, Arnault E, Husson Z, Froger N, Dubus E, Gondouin P, Dherbecourt D, Degardin J, Simonutti M, Fouquet S, Benahmed MA, Elbayed K, Namer IJ, Massin P, Sahel JA, Picaud S (2012) Taurine deficiency damages retinal neurones: cone photoreceptors and retinal ganglion cells. Amino Acids 43:1979–1993PubMedCrossRefGoogle Scholar
  10. Hayes KC, Carey RE, Schmidt SY (1975) Retinal degeneration associated with taurine deficiency in the cat. Science 188:949–951PubMedCrossRefGoogle Scholar
  11. Heller-Stilb B, van Roeyen C, Rascher K, Hartwig HG, Huth A, Seeliger MW, Warskulat U, Haussinger D (2002) Disruption of the taurine transporter gene (taut) leads to retinal degeneration in mice. FASEB J 16:231–233PubMedGoogle Scholar
  12. Hillenkamp J, Hussain AA, Jackson TL, Constable PA, Cunningham JR, Marshall J (2004) Compartmental analysis of taurine transport to the outer retina in the bovine eye. Invest Ophthalmol Vis Sci 45:4099–4105PubMedCrossRefGoogle Scholar
  13. Huxtable RJ (1989) Taurine in the central nervous system and the mammalian actions of taurine. Prog Neurobiol 32:471–533PubMedCrossRefGoogle Scholar
  14. Jammoul F, Degardin J, Pain D, Gondouin P, Simonutti M, Dubus E, Caplette R, Fouquet S, Craft CM, Sahel JA, Picaud S (2010) Taurine deficiency damages photoreceptors and retinal ganglion cells in vigabatrin-treated neonatal rats. Mol Cell Neurosci 43:414–421PubMedCrossRefGoogle Scholar
  15. Jammoul F, Wang Q, Nabbout R, Coriat C, Duboc A, Simonutti M, Dubus E, Craft CM, Ye W, Collins SD, Dulac O, Chiron C, Sahel JA, Picaud S (2009) Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol 65:98–107PubMedCrossRefGoogle Scholar
  16. Le Meur G, Stieger K, Smith AJ, Weber M, Deschamps JY, Nivard D, Mendes-Madeira A, Provost N, Pereon Y, Cherel Y, Ali RR, Hamel C, Moullier P, Rolling F (2007) Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium. Gene Ther 14:292–303PubMedCrossRefGoogle Scholar
  17. Madl JE, McIlnay TR, Powell CC, Gionfriddo JR (2005) Depletion of taurine and glutamate from damaged photoreceptors in the retinas of dogs with primary glaucoma. Am J Vet Res 66:791–799PubMedCrossRefGoogle Scholar
  18. Pasantes-Morales H, Quiroz H, Quesada O (2002) Treatment with taurine, diltiazem, and vitamin E retards the progressive visual field reduction in retinitis pigmentosa: a 3-year follow-up study. Metab Brain Dis 17:183–197PubMedCrossRefGoogle Scholar
  19. Pasantes-Morales H, Quesada O, Carabez A, Huxtable RJ (1983) Effects of the taurine transport antagonist, guanidinoethane sulfonate, and beta-alanine on the morphology of rat retina. J Neurosci Res 9:135–143PubMedCrossRefGoogle Scholar
  20. Rascher K, Servos G, Berthold G, Hartwig HG, Warskulat U, Heller-Stilb B, Haussinger D (2004) Light deprivation slows but does not prevent the loss of photoreceptors in taurine transporter knockout mice. Vision Res 44:2091–2100PubMedCrossRefGoogle Scholar
  21. Ravindran J, Blumbergs P, Crompton J, Pietris G, Waddy H (2001) Visual field loss associated with vigabatrin: pathological correlations. J Neurol Neurosurg Psychiatry 70:787–789PubMedCrossRefGoogle Scholar
  22. Rosolen SG, Saint-MacAry G, Gautier V, Legargasson JF (2001) Ocular fundus images with confocal scanning laser ophthalmoscopy in the dog, monkey and minipig. Vet Ophthalmol 4:41–45PubMedCrossRefGoogle Scholar
  23. Rosolen SG, Riviere ML, Lavillegrand S, Gautier B, Picaud S, Legargasson JF (2012) Use of a combined slit-lamp SD-OCT to obtain anterior and posterior segment images in selected animal species. Vet Ophthalmol 15 (suppl.2):105–115PubMedCrossRefGoogle Scholar
  24. Schmidt SY, Aguirre GD (1985) Reductions in taurine secondary to photoreceptor loss in Irish setters with rod-cone dysplasia. Invest Ophthalmol Vis Sci 26:679–683PubMedGoogle Scholar
  25. Shao A, Hathcock JN (2008) Risk assessment for the amino acids taurine, L-glutamine and L-arginine. Regul Toxicol Pharmacol 50:376–399PubMedCrossRefGoogle Scholar
  26. Tao W, Wen R, Goddard MB, Sherman SD, O’Rourke PJ, Stabila PF, Bell WJ, Dean BJ, Kauper KA, Budz VA, Tsiaras WG, Acland GM, Pearce-Kelling S, Laties AM, Aguirre GD (2002) Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci 43:3292–3298PubMedGoogle Scholar
  27. Wild JM, Robson CR, Jones AL, Cunliffe IA, Smith PE (2006) Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest Ophthalmol Vis Sci 47:917–924PubMedCrossRefGoogle Scholar
  28. Yamori Y, Liu L, Mori M, Sagara M, Murakami S, Nara Y, Mizushima S (2009) Taurine as the nutritional factor for the longevity of the Japanese revealed by a world-wide epidemiological survey. Adv Exp Med Biol 643:13–25PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Serge-George Rosolen
    • 1
    • 2
    • 3
    • 4
    • 5
    Email author
  • Nathalie Neveux
    • 6
    • 7
  • José-Alain Sahel
    • 3
    • 4
    • 5
    • 8
    • 9
    • 10
    • 11
  • Serge Picaud
    • 3
    • 4
    • 5
    • 8
    • 10
  • Nicolas Froger
    • 3
    • 4
    • 5
    • 8
  1. 1.Réseau Européen d’Ophtalmologie Vétérinaire et de Vision Animale (REOVVA)AsnièresFrance
  2. 2.Clinique Vétérinaire VoltaireAsnièresFrance
  3. 3.INSERM, U968, Institut de la VisionParisFrance
  4. 4.UPMC Université Paris 06, UMR_S 968, Institut de la VisionParisFrance
  5. 5.CNRS, UMR 7210, Institut de la VisionParisFrance
  6. 6.Stress cellulaire: Physiopathologie, stratégies nutritionnelles et thérapeutiques innovantes, EA 4466, Faculté de PharmacieUniversité Descartes Paris VParisFrance
  7. 7.Service Inter-hospitalier de biochimie, CHU Cochin-St-Vincent de Paul, AP-HPParisFrance
  8. 8.Centre Hospitalier National d’Ophtalmologie des Quinze-VingtsParisFrance
  9. 9.Institute of OphthalmologyUniversity College of LondonLondonUK
  10. 10.Fondation Ophtalmologique Adolphe de RothschildParisFrance
  11. 11.French Academy of SciencesParisFrance

Personalised recommendations